| 摘要 |
The present invention relates to a pro-drug (M-Z) comprising an antitumoraltherapeutic compound (M), having an active intracellular site, bound to aligand (Z), wherein the bond between the ligand (Z) and the antitumoraltherapeutic compound (M) prevents the intracellular penetration of thepro-drug (M-Z) and wherein the bond is selectively cleavable by factorssecreted by tumour cells so as to enable the penetration of the therapeuticagent (M) or its precursor (M*) into said tumour cells, characterised inthat the ligand (Z) comprises at least one group (W) selected from the groupformed by amino acids not present in mammals and D amino acids, ensuring thestabilisation of the pro-drug in the serum and circulating blood.<IMAGE> |
